checkAd
    Startseite > Aktien > Sosei Group > Nachrichten
    Sosei Group Aktie
    8,5250
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 19:00:48 Lang & Schwarz
    8,3500
     
    EUR
    51 STK
    Geldkurs 19:00:48
    8,7000
     
    EUR
    51 STK
    Briefkurs 19:00:48
    ISIN: JP3431300007 · WKN: A0B7EK · Japan

    Neueste Nachrichten

    Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
    30.05.24 · globenewswire · Sosei Group
    Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
    30.05.24 · globenewswire · Sosei Group
    Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
    09.05.24 · globenewswire · Sosei Group
    Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
    09.05.24 · globenewswire · Sosei Group
    Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
    17.04.24 · globenewswire · Sosei Group
    Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
    16.04.24 · globenewswire · Sosei Group
    Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ in South Korea
    15.04.24 · globenewswire · Sosei Group
    Nxera Pharma joins the World Orphan Drug Alliance
    08.04.24 · globenewswire · Sosei Group
    Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC
    03.04.24 · globenewswire · Sosei Group
    Nxera Pharma is the New Name for Sosei Group
    01.04.24 · globenewswire · Sosei Group
    Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
    27.03.24 · globenewswire · Sosei Group
    Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
    21.03.24 · globenewswire · Sosei Group